Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Feature

Perspectives
Frameworks for Assessing the Value of Cancer Drugs: Purely an Academic Exercise?
08/02/2016
Joshua P Cohen, PhD
Abstract: As the cost of prescription drugs increases, payers and providers alike have attempted to determine the value of treatments for high-cost disease, including cancer. In this article, the authors discuss the...
Abstract: As the cost of prescription drugs increases, payers and providers alike have attempted to determine the value of treatments for high-cost disease, including cancer. In this article, the authors discuss the...
...
08/02/2016
Journal of Clinical Pathways
From the Field
A Method of Deriving Estimates of Health State Utilities for Patients With Metastatic Breast Cancer
06/20/2016
Stacie Hudgens, MA
Andrew Briggs, DPhil, MSc
Anna Forsythe, PharmaD, MBA, MSc
Gabriel Tremblay, DBA, MSc
Andrew J Lloyd, DPhil
Abstract Patient-level health-related quality of life (HRQOL) for different stages of metastatic breast cancer (MBC) and chemotherapy regimen toxicities are useful for health economic assessments. However, it is...
Abstract Patient-level health-related quality of life (HRQOL) for different stages of metastatic breast cancer (MBC) and chemotherapy regimen toxicities are useful for health economic assessments. However, it is...
...
06/20/2016
Journal of Clinical Pathways

Advertisement

Research Reports
SEASONS: A Prospective Study to Assess the Physical, Psychosocial, Spiritual, and Financial Needs of Breast and Prostate Cancer Survivors
06/20/2016
Nancy Ehmke, RN, MN, AOCN
Breck Hunnicutt, RN, BSN, CCRC
Hilary Biddle RN, BSN, CCRC
Christina Zelt, RN, MSN
Brooke Hoverman
Stephanie Trenkner, BS
Carlena Magley, BS
Abstract: As cancer centers expand survivorship services beyond the delivery of the care plan to provide educational programs and support services, it is critical to assess survivors’ needs throughout their...
Abstract: As cancer centers expand survivorship services beyond the delivery of the care plan to provide educational programs and support services, it is critical to assess survivors’ needs throughout their...
...
06/20/2016
Journal of Clinical Pathways
From the Field
Mock Clinical Pathways: A Method for Exploring the Oncology Clinical Pathway Development Process
05/06/2016
Bruce Feinberg, DO
Monica Lingam, MS
Bing-E Xu, PhD
Abstract: Clinical pathways are a critical structural element in the effort to reduce variation in health care as well as to make costs and outcomes more predictable, measurable, and accountable. A mock clinical...
Abstract: Clinical pathways are a critical structural element in the effort to reduce variation in health care as well as to make costs and outcomes more predictable, measurable, and accountable. A mock clinical...
...
05/06/2016
Journal of Clinical Pathways
Research Reports
Cost-Effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19 Deletion Mutations
05/06/2016
Jonathan Graham, BS
Stephanie Earnshaw, PhD
Jonathan Lim, BS, MS, MSc
Rakesh Luthra, MS
Rohit Borker, PhD
Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...
Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...
...
05/06/2016
Journal of Clinical Pathways

Advertisement

From the Field
Development and Implementation of De Novo Clinical Decision Support Rules at a Tertiary Cancer Center
04/11/2016
Aymen Elfiky, MD, MPH, MSc
Marina Kaymakcalan, PharmD
Abstract: The rising costs associated with cancer care delivery have prompted the health care system to prioritize the principle of value-based care to accentuate the concepts of quality and outcomes. Driven in...
Abstract: The rising costs associated with cancer care delivery have prompted the health care system to prioritize the principle of value-based care to accentuate the concepts of quality and outcomes. Driven in...
...
04/11/2016
Journal of Clinical Pathways
Research Reports
Health Care Use and Costs Among Medicare Patients With Chronic Obstructive Pulmonary Disease Treated With Short-Acting Beta Agonists or Long-Acting Beta Agonists
04/11/2016
Flavia Ejzykowicz, PhD
Vamsi K Bollu, PhD, MBA
Krithika Rajagopalan, PhD
Joel W Hay, PhD
Abstract: Chronic obstructive pulmonary disease (COPD) has a high prevalence among older adults and is the third leading cause of mortality in the United States. COPD exacerbations can require hospitalizations,...
Abstract: Chronic obstructive pulmonary disease (COPD) has a high prevalence among older adults and is the third leading cause of mortality in the United States. COPD exacerbations can require hospitalizations,...
...
04/11/2016
Journal of Clinical Pathways
Perspectives
Impact of Government Cost Controls on Treatment Selection for Clinical Pathways
03/08/2016
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD
Scott Guerin, PhD
Abstract: The increasing emphasis on value-based care has led to the rise of clinical pathways and their use in various health care settings for a number of different disease states. To improve these pathways and...
Abstract: The increasing emphasis on value-based care has led to the rise of clinical pathways and their use in various health care settings for a number of different disease states. To improve these pathways and...
...
03/08/2016
Journal of Clinical Pathways

Advertisement

Research Reports
Effect of Route of Bortezomib Administration on Treatment Outcomes in Previously Untreated Patients with Multiple Myeloma: A Retrospective Analysis from US Community Oncology Practices
03/08/2016
Robert M Rifkin, MD, FACP
Esprit Ma, MPH
Robyn Harrell, MS
Lina Asmar, PhD
Yanyan Zhu, PhD, MPH
Liviu Niculescu, MD
Vijayveer Bonthapally, PhD
Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV) bortezomib....
Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV) bortezomib....
...
03/08/2016
Journal of Clinical Pathways
Perspectives
The Role of Patient Navigation in Improving the Value of Oncology Care
02/16/2016
Sheryl Riley, RN, OCN, CMCN
Cortney Riley, BS, DPT
Abstract: Today, cancer patients face many challenges when trying to understand and navigate the health care system. These challenges begin at the time of diagnosis and continue throughout treatment, follow-up care,...
Abstract: Today, cancer patients face many challenges when trying to understand and navigate the health care system. These challenges begin at the time of diagnosis and continue throughout treatment, follow-up care,...
...
02/16/2016
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use